238 related articles for article (PubMed ID: 18068869)
21. Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
Cirioni O; Giacometti A; Ghiselli R; Orlando F; Kamysz W; D'Amato G; Mocchegiani F; Lukasiak J; Silvestri C; Saba V; Scalise G
J Infect Dis; 2004 Jul; 190(2):356-64. PubMed ID: 15216473
[TBL] [Abstract][Full Text] [Related]
22. Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum.
Bette M; Nüsing RM; Mutters R; Zamora ZB; Menendez S; Schulz S
Shock; 2006 Jan; 25(1):23-9. PubMed ID: 16369182
[TBL] [Abstract][Full Text] [Related]
23. Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo.
Bönig HB; Hannen M; Lex C; Wölfel S; Banning U; Nürnberger W; Körholz D; Göbel U
Cancer; 1999 Jul; 86(2):340-8. PubMed ID: 10421271
[TBL] [Abstract][Full Text] [Related]
24. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
25. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
[TBL] [Abstract][Full Text] [Related]
26. Amphibian peptides prevent endotoxemia and bacterial translocation in bile duct-ligated rats.
Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Silvestri C; Orlando F; Kamysz W; Licci A; Kamysz E; Lukasiak J; Saba V; Scalise G
Crit Care Med; 2006 Sep; 34(9):2415-20. PubMed ID: 16791114
[TBL] [Abstract][Full Text] [Related]
27. Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli.
Wu G; Fan X; Li L; Wang H; Ding J; Hongbin W; Zhao R; Gou L; Shen Z; Xi T
Int J Antimicrob Agents; 2010 Mar; 35(3):250-4. PubMed ID: 20045294
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain.
Cirioni O; Ghiselli R; Orlando F; Silvestri C; Mocchegiani F; Rocchi M; Chiodi L; Abbruzzetti A; Saba V; Scalise G; Giacometti A
Crit Care Med; 2007 Jul; 35(7):1717-23. PubMed ID: 17452938
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy of granulocyte colony stimulating factor against rat cecal ligation and puncture model.
Toda H; Murata A; Matsuura N; Uda K; Oka Y; Tanaka N; Mori T
Stem Cells; 1993 May; 11(3):228-34. PubMed ID: 7686420
[TBL] [Abstract][Full Text] [Related]
30. The effects of G-CSF treatment and starvation on bacterial translocation in hemorrhagic shock.
Agalar F; Iskit AB; Agalar C; Hamaloglu E; Guc MO
J Surg Res; 1998 Aug; 78(2):143-7. PubMed ID: 9733632
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
32. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
[TBL] [Abstract][Full Text] [Related]
33. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.
Tan XX; Actor JK; Chen Y
Antimicrob Agents Chemother; 2005 Aug; 49(8):3203-7. PubMed ID: 16048926
[TBL] [Abstract][Full Text] [Related]
34. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
Kuck NA; Petersen PJ; Weiss WJ; Jacobus NV; Testa RT; Tally FP
J Chemother; 1989 Jul; 1(4 Suppl):105-6. PubMed ID: 16312325
[No Abstract] [Full Text] [Related]
35. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
[TBL] [Abstract][Full Text] [Related]
36. Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock.
Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Viticchi C; Orlando F; D'Amato G; Del Prete MS; Kamysz W; łLukasiak J; Saba V; Scalise G
Peptides; 2003 Nov; 24(11):1747-52. PubMed ID: 15019206
[TBL] [Abstract][Full Text] [Related]
37. Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.
Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Orlando F; Silvestri C; Bozzi A; Di Giulio A; Luzi C; Mangoni ML; Barra D; Saba V; Scalise G; Rinaldi AC
Antimicrob Agents Chemother; 2006 Jul; 50(7):2478-86. PubMed ID: 16801429
[TBL] [Abstract][Full Text] [Related]
38. The granulocyte colony-stimulating factor response after intrapulmonary and systemic bacterial challenges.
Quinton LJ; Nelson S; Boé DM; Zhang P; Zhong Q; Kolls JK; Bagby GJ
J Infect Dis; 2002 May; 185(10):1476-82. PubMed ID: 11992284
[TBL] [Abstract][Full Text] [Related]
39. Experimental Induction of Bacterial Resistance to the Antimicrobial Peptide Tachyplesin I and Investigation of the Resistance Mechanisms.
Hong J; Hu J; Ke F
Antimicrob Agents Chemother; 2016 Oct; 60(10):6067-75. PubMed ID: 27480861
[TBL] [Abstract][Full Text] [Related]
40. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Lipsky BA; Giordano P; Choudhri S; Song J
J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
